Compare DRUG & OPK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DRUG | OPK |
|---|---|---|
| Founded | 2019 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 707.1M | 921.2M |
| IPO Year | 2020 | 2011 |
| Metric | DRUG | OPK |
|---|---|---|
| Price | $73.58 | $1.20 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $124.00 | $2.03 |
| AVG Volume (30 Days) | 79.2K | ★ 1.9M |
| Earning Date | 01-01-0001 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $606,879,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.76 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $23.18 | $1.11 |
| 52 Week High | $123.75 | $1.87 |
| Indicator | DRUG | OPK |
|---|---|---|
| Relative Strength Index (RSI) | 39.66 | 48.65 |
| Support Level | $72.06 | $1.12 |
| Resistance Level | $84.29 | $1.27 |
| Average True Range (ATR) | 4.41 | 0.04 |
| MACD | -1.05 | 0.00 |
| Stochastic Oscillator | 18.19 | 50.00 |
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.